Battered Amarin finally lands a partner for Vascepa

After a rough go with the FDA sent its shares spiraling downward, Amarin ($AMRN) has at last found a partner to help commercialize its fish-oil-derived pill for high triglycerides. The biotech has teamed up with Japanese statin specialist Kowa Pharmaceuticals to nearly triple its U.S. sales force and try to move the needle on Vascepa, which has been a commercial disappointment since winning FDA approval in 2012. Article

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.